Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma

We evaluated the impact on progression-free survival (PFS) of achieving a deep metabolic response at 2-deoxy-2[18F] fluoro-d-glucose positron emission tomography (FDG-PET) in patients with refractory or relapsed (R/R) classic Hodgkin lymphoma (cHL) following a new salvage regimen named Bv+Bs (brentu...

Full description

Saved in:
Bibliographic Details
Published in:Blood advances 2019-05, Vol.3 (9), p.1546-1552
Main Authors: Picardi, M., Della Pepa, R., Giordano, C., Pugliese, N., Mortaruolo, C., Trastulli, F., Rascato, M.G., Cappuccio, I., Raimondo, M., Memoli, M., Monteverde, M., Mascolo, M., Pane, F.
Format: Article
Language:English
Subjects:
Adult
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Bendamustine Hydrochloride - adverse effects
Bendamustine Hydrochloride - therapeutic use
Brentuximab Vedotin - adverse effects
Brentuximab Vedotin - therapeutic use
Clinical Trials and Observations
Female
Follow-Up Studies
Hematopoietic Stem Cell Transplantation
Hodgkin Disease - diagnosis
Hodgkin Disease - drug therapy
Hodgkin Disease - mortality
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Neutropenia - etiology
Positron-Emission Tomography
Progression-Free Survival
Recurrence
Transplantation, Autologous
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the impact on progression-free survival (PFS) of achieving a deep metabolic response at 2-deoxy-2[18F] fluoro-d-glucose positron emission tomography (FDG-PET) in patients with refractory or relapsed (R/R) classic Hodgkin lymphoma (cHL) following a new salvage regimen named Bv+Bs (brentuximab vedotin + bendamustine supercharge), from 2013 to 2017. In this real-life study, 20 consecutive patients (aged
ISSN:2473-9529
2473-9537
DOI:10.1182/bloodadvances.2019000123